Inanovate was founded in 2005 by David Ure and David Arslanian, based on a unique nano-scale surface fabrication technology developed at the Nano-Scale Physics Research Laboratory at the University of Birmingham (UK). This novel approach to surface fabrication led to Inanovate’s first product, a protein biochip substrate platform called the i-Slide™. Since validating the i-Slide™, Inanovate has both developed and acquired additional technology to support the development of a diagnostic platform for cancer detection. Inanovate now has operations in both the US and UK, with industry leading expertise and facilities crossing business, biology, chemistry, physics, and nano-scale engineering, providing a unique and powerful base to continue to grow as a leader in clinical and pre-clinical protein biochip systems.

The above photo shows Inanovate's proprietary nano-particle biochip production system at our UK facilities. This system was developed through a consortium with Teer Coatings Ltd and the University of Birmingham, and was supported by a UK Technology Strategy Board grant under the prestigious Micro and Nano Technology (MNT) program.

Inanovate's many achievements to date include:

• Development of a team that comprises extensive expertise in business, biotechnology, chemistry, diagnostics and nano-scale engineering.
• Development of facilities at the cutting edge of nano-scale surface fabrication and protein biochip technology.
• Awarded prestigious government grants through the UK's Technology Strategy Board, SMART Cymru and Advantage West Midlands.
• Acceptance onto prestigious loan programs through the North Carolina Biotechnology Center.
• Ongoing strong collaborations and strategic partnerships with institutions such as Harvard Medical School, the University of Birmingham, Johnston Matthey, and Teer Coatings.
• Ongoing support through private venture financing.
• Winning the prestigious Babson Business Plan competition for most promising new business in 2006.